Radiologists are confident about keeping pace with advancements in the field but acknowledge challenges and opportunities. Harnessing Artificial Intelligence (AI), healthcare spending, and attracting future talent are the foremost challenges.
"These survey results inspire us to continue advancing innovation in 2023 and beyond," said Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging. "Whether we're talking about the promise of AI in diagnostic imaging or the clinical value of new contrast agents, a key takeaway for the diagnostic imaging industry at large, is that the road to innovation often lacks involvement from radiologists themselves. By bringing in the perspectives of those on the frontlines, through surveys such as this and other means, Bracco continues to hone our focus for where to improve techniques and processes in ways that will maximize clinical benefits."
Ad Statistics
Times Displayed: 173298
Times Visited: 3160 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Additional key insights from the survey include:
More than a quarter (26%) of radiologists experienced issues with the availability of gadolinium-based contrast agents in the past few years.
While there is some concern (46%) about the use of gadolinium-based contrast agents, there is greater concern about the amount of gadolinium-based contrast agents (86%).
Just over a third of radiologists (35%) say their patients express concerns about MRI contrast agents used in their bodies – no surprise considering 41% of radiologists say their patients are more informed about MRI contrast agents than just a few years ago.
More than a third of radiologists (35%) are thinking about environmental impact and sustainability more than they did a few years ago.
The online survey captures quantitative data from 200 radiologists (20 Technologists/Technicians, 164 MRI Radiologists/Chief Radiologists, and 16 Imaging Directors) between October 26 through November 4, 2022. The majority of respondents work in a hospital (147), with imaging centers (40) and outpatient departments (13) also being represented.
VUEWAY™ (gadopiclenol) injection Important Safety Information
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
See full prescribing information for complete boxed warning
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.
The risk for NSF appears highest among patients with:
